Will The DEA Complete Cannabis Rescheduling? Hear From Experts The Day After Harris-Trump Debate

One day after the September Tuesday’s presidential debate, industry experts will break down the cannabis rescheduling process, a crucial issue for investors. Equity research firm Z&A is hosting a webinar on Wednesday at 4:20 PM ET to provide insights into the upcoming regulatory shifts and market implications.

Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

DEA's Rescheduling Process

The conversation comes at a pivotal moment following the end of the public comment period for the DEA to reschedule cannabis from Schedule I to Schedule III. Proposed by the Department of Justice on May 21 2024, the move was met with positive responses, as 75.9% of over 4,000 public comments analyzed by Benzinga Cannabis showed support for rescheduling, mainly due to the medical benefits and alignment with state laws.

DEA Rescheduling Delay

On August 27, 2024, the DEA announced a delay in its final ruling until after the November election.

This triggered sharp declines in cannabis stocks, with the AdvisorShares Pure US Cannabis ETF MSOS dropping over 10%. Major players like Curaleaf Holdings CURLF, Cresco Labs CRLBF, and Cansortium CNTMF saw stock prices plunge by as much as 16%.

Investor's Angle: Upcoming Panel Post-Debate Chaos

If cannabis is reclassified, the industry could see significant changes such as tax reforms, enhanced research opportunities and the development of new regulatory frameworks.

This is where the insights from experts like Kelly Fair and Morgan Fox become crucial. Fair, a partner at Dentons, specializes in regulatory compliance and corporate governance within the cannabis sector. With nearly two decades of experience, she will provide in-depth perspectives on the technical aspects of the rescheduling process, the role of the DEA and possible legal outcomes. 

Meanwhile, Fox, the political director at NORML, will focus on the political landscape. With over 15 years of experience in cannabis policy reform, Fox will explain why descheduling remains the ultimate goal and how rescheduling fits into the bigger picture of cannabis reform.

Co-hosted by senior analyst Pablo Zuanic from Zuanic & Associates, and Anthony Coniglio, CEO of NewLake Capital Partners NLCP, the panel promises to shed light on the future of cannabis regulation, particularly in light of the September 10th presidential debate.

Read Next: Top Dem Congressman Calls Trump’s Cannabis Support A ‘Powerful Signal’ To GOP: ‘When Even Donald Trump Can Get On Board…’

Z&A SPACES ON S3 RESCHEDULING:
Dentons' Kelly Fair and NORML's Morgan Fox will discuss the technical and political aspects of S3 Rescheduling & future developments (bifurcation? MMJ legalization? De-scheduling?

Z&A's @420Odysseus & NLCP's @AnthonyConigli0 will host (Wed Sep 11 @… pic.twitter.com/iMLzlfsIyE

— Pablo Zuanic (@420Odysseus) September 7, 2024